ORIG3N, a Boston, MA-based biotechnology company, raised $3.1m in funding.
Backers included Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.
The company intends to use the funds to expand its Life Capsule™.
Led by Robin Y. Smith, CEO and co-founder, ORIG3N is developing a disease-modeling platform targeting rare genetically inherited diseases. Its Life Capsule is a bio-repository where anyone can contribute to the advancement of medicine and their own future health. From the collection of a small amount of blood, the cells are reprogramed into induced pluripotent stem cells (iPSCs), which can be used for disease modeling outside of the body for both critical medical research and individualized therapy.
FinSMEs
06/02/2015